NCT02834390 Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Status COMPLETED Phase PHASE1
NCT02828358 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Status COMPLETED Phase PHASE2
NCT02813135 European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT02797470 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT02791919 Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Status WITHDRAWN Phase PHASE1
NCT02779283 Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE1
NCT02756962 Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02756572 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Status COMPLETED Phase PHASE2
NCT02741388 A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP Status COMPLETED Phase PHASE1
NCT02728531 Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma Status COMPLETED Phase PHASE1
NCT02728050 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Status COMPLETED Phase PHASE1/PHASE2
NCT02724163 International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02723994 A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Status COMPLETED Phase PHASE2
NCT02719574 Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation Status COMPLETED Phase PHASE1/PHASE2
NCT02718755 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Status WITHDRAWN Phase PHASE2
NCT02717884 Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) Status UNKNOWN Phase PHASE1/PHASE2
NCT02688140 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Status COMPLETED Phase PHASE3
NCT02680951 Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia Status WITHDRAWN Phase PHASE1
NCT02676323 Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Status TERMINATED Phase PHASE1